Memorandum of Understanding (MOU) concluded with the Siriraj Institute of Clinical Research (SICRES), Siriraj Hospital, Mahidol University in Thailand　Aiming for 100 Days Mission, Remedy signed MOUs with 13 Institutions in 9 countries over the year, covering the entire Global South, where infectious diseases are prevalent, to propose optimal clinical development plans.

We are pleased to announce that Remedy & Company (Chiyoda-ku, Tokyo, Founder and CEO Masakuni Ukita ) has signed an MOU as of December 17, 2024, with the Siriraj Institute of Clinical Research (hereinafter referred to as “SICRES”), the clinical research center of Sirirat Hospital, Mahidol University, Thailand. This agreement aims to establish a cooperative framework to promote clinical trials on infectious diseases such as dengue fever and malaria.

The Faculty of Tropical Medicine at Mahidol University, with whom we signed an MOU in March last year, has some of the most extensive experience in Asia in the treatment and clinical development of NTDs and infectious diseases. By signing an MOU with SICRES, the university's clinical research arm, we are now able to provide support for clinical trials in the field of infectious diseases that meet international quality standards, as well as offer clinical development environments for various NTDs.*
Furthermore, with the signing of the MOU with SICRES, the number of potential participants for our "Infectious Disease Global Development Platform" has expanded to approximately 150,000 individuals.
Thailand is one of the countries where infectious diseases such as dengue fever and malaria are widespread. It has the highest number of ongoing clinical trials in Southeast Asia, at 44 (as of December 2024, according to ClinicalTrials.gov). Many physicians are actively working on clinical development.

Thailand is also actively engaged in CHIM (Controlled Human Infection Model) trials, for evaluating vaccines and therapeutics on a small scale over a short period of time. It is expected that CHIM trials will be promoted in Asia in the future.

Remedy & Company, as a Japan-based Healthtech platform, is promoting our global business with the goal of achieving the "100 Days Mission". This mission aims to tackle infectious diseases for which no treatments have been established anywhere in the world, and to develop and commercialise diagnostic drugs, therapeutic drugs, and vaccines within 100 days in the event of a pandemic caused by an unknown virus.

In 2024, we signed MOUs with 13 institutions in 9 countries to promote clinical trials for infectious diseases. This strengthened the network and capabilities of the "Infectious Disease Global Development Platform," which was launched in 2021, and enabled updates in the regions and infectious disease areas that can be proposed to our clients.

In 2025, we are going to combining these networks with our knowledge and experience in clinical development in the global south, including Southeast Asia, South Asia, South America, and Africa, to further build a system that can provide total support, from formulating development strategies to conducting local clinical trials, as a leader in the field of infectious diseases.

■What is Infectious Disease Global Development Platform

The service was launched to support the rapid clinical development of existing infectious diseases, such as NTDs like dengue fever, as well as the three major infectious diseases like tuberculosis and malaria. It also aims to assist in the development and commercialisation of safe and effective vaccines and treatments within 100 days in the event of a pandemic caused by an unknown virus.
We have incorporated the necessary elements to enable rapid clinical development, such as shortening the subject recruitment period by acquiring a total of 100,000 subject candidates in Southeast Asia, South America, and Africa even in peacetime, and developing in-house the MUGEN EDC data collection system, which can be built up in a short period of time.

We also have know-how on the actual status of infectious diseases and racial characteristics in various regions of the world, experience in conducting large-scale clinical trials overseas after the pandemic disaster of the new coronavirus, and a network of research institutes, CROs, SMOs, and KOLs in various infectious diseases in countries around the world. We design and propose the most appropriate clinical trial countries and clinical development plans that meet the needs of our clients in terms of time, cost, and other factors.

*What is NTDs
NTDs is an abbreviation for "Neglected Tropical Diseases" which refers to diseases identified by the World Health Organisation (WHO) as "tropical diseases that humanity must overcome." These diseases are prevalent in impoverished regions of the world where access to safe water, sanitation, and healthcare is limited. They are estimated to affect over 1 billion people worldwide, not only impoverishing individuals' lives and economies but also hindering entire countries and regions from escaping poverty.

*What is 100 Days Mission
This is an international goal to achieve the practical implementation of "Medical Countermeasures (MCM)"—such as the approval of rapid diagnostic tools, the approval of safe and effective vaccines, and the establishment of treatments—within 100 days after the World Health Organisation (WHO) declares a "Public Health Emergency of International Concern (PHEIC)" for a new infectious disease. Proposed as the "100 Days Mission (100DM)" at the G7 Summit held in the UK in June 2021, this initiative was introduced in response to challenges highlighted by the global spread of COVID-19.

List of Institutions with MOU signed:

• MOU with Mahidol University, Thailand
  https://www.remedy-company.com/en/news/2024/20240329.html
• MOU with the Ministry of Health of Indonesia and Clinical Research Coordinator INDONESIA
  https://www.remedy-company.com/en/news/2024/20240612.html
• MOU with Airlangga University Hospital, Indonesia
  https://www.remedy-company.com/en/news/2024/20240613.html
• MOU with the private Cayetano Heredia University, Peru
  https://www.remedy-company.com/en/news/2024/20240718.html
• Industry's First! Infectious Disease Global Development Platform for the 100-Days Mission (Japanese)
  https://www.remedy-company.com/news/2024/20240326.html

About Remedy & Company:
Remedy & Company was established in 2018, evolving from the CRO business of intellim Corporation, which was founded in 2005. As a core company leading both domestic and international group companies, Remedy & Company has been working on creating innovative solutions in pharmaceutical development worldwide. With the change of name, the company has embarked on a new journey, aiming to become a global healthtech platform beyond the scope of a CRO. Remedy & Company is deploying its business globally from Japan, utilising the latest technologies and XR technology to solve various medical challenges.
Group Companies：intellim Corporation, iRIS Corporation, Quantum Healthcare Corporation, Remedy XR Corporation

Group Locations：7 countries Project Implementation Countries: 42 countries (as of January 2025)
For more details, please visit：https://www.remedy-company.com/en/